TOP TEN perturbations for 102_at (Homo sapiens)

Organism: Homo sapiens
Gene: 102_at
Selected probe(set): 226297_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 102_at (226297_at) across 6672 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):4.094964
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-3.8450708
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.4616547
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.8641586
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

HCT 116 DICER1(-/-) / p53HCT116

Relative Expression (log2-ratio):2.460411
Number of Samples:3 / 3
Experimental HCT 116 DICER1(-/-)
Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout DICER gene in exon 5 by using an AAV targeting construct. Parental cell line:: HCT 116 Synonyms:DICER1 (-/-) HCT116; HCT116 DICEREX5/EX5, DICERex5 Cellosaurus code:
Control p53HCT116
Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout gene for p53. Parental cell line:: HCT 116 Synonyms:P53HCT116; p53-/- HCT116; p53(-/-) HCT-116; HCT116-p53-/-; HCT116-p53 Cellosaurus code:

nonspecific orbital inflammatory disease study 1 (lacrimal gland tissue) / normal lacrimal gland tissue

Relative Expression (log2-ratio):-2.253951
Number of Samples:42 / 7
Experimental nonspecific orbital inflammatory disease study 1 (lacrimal gland tissue)
Lacrimal gland tissue samples obtained from patients who suffered from nonspecific orbital inflammatory disease (NSOI). Biopsies were formalin-fixed and paraffin-embedded.
Control normal lacrimal gland tissue
Normal lacrimal gland tissue samples. The control tissue was obtained during surgery on eyes with non-inflamed orbits, such as blepharoplasties and enucleations. Biopsies were formalin-fixed and paraffin-embedded.

sarcoidosis study 6 (orbital adipose tissue) / normal orbital adipose tissue

Relative Expression (log2-ratio):-2.241685
Number of Samples:7 / 22
Experimental sarcoidosis study 6 (orbital adipose tissue)
Orbital adipose tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded.
Control normal orbital adipose tissue
Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.219162
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

Huntington's disease study 16 (batch L) / control blood sample

Relative Expression (log2-ratio):2.1508865
Number of Samples:8 / 231
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control control blood sample
Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.

Huntington's disease study 16 (batch L) / Parkinson's disease study 32 (IPD)

Relative Expression (log2-ratio):2.0819206
Number of Samples:8 / 205
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control Parkinson's disease study 32 (IPD)
Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.